{"organizations": [], "uuid": "f755a659c643c0a6e2d614b9f44fc9884199a764", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180508.html", "section_title": "Archive News &amp; Video for Tuesday, 08 May 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-redhill-biopharma-posts-q1-loss-of/brief-redhill-biopharma-posts-q1-loss-of-0-05-per-ordinary-share-idUSASC0A0EV", "country": "US", "domain_rank": 408, "title": "BRIEF-Redhill Biopharma Posts Q1 Loss Of $0.05 Per Ordinary Share", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.088, "site_type": "news", "published": "2018-05-08T19:30:00.000+03:00", "replies_count": 0, "uuid": "f755a659c643c0a6e2d614b9f44fc9884199a764"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-redhill-biopharma-posts-q1-loss-of/brief-redhill-biopharma-posts-q1-loss-of-0-05-per-ordinary-share-idUSASC0A0EV", "ord_in_thread": 0, "title": "BRIEF-Redhill Biopharma Posts Q1 Loss Of $0.05 Per Ordinary Share", "locations": [], "entities": {"persons": [], "locations": [{"name": "us", "sentiment": "none"}], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "redhill biopharma ltd", "sentiment": "negative"}, {"name": "crohn", "sentiment": "none"}, {"name": "redhill biopharma", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "May 8 (Reuters) - Redhill Biopharma Ltd:\n* REDHILL BIOPHARMA REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS\n* Q1 REVENUE $2.4 MILLION * REDHILL BIOPHARMA - DOES NOT HAVE PLANS TO RAISE ADDITIONAL CAPITAL AHEAD OF MAP US PHASE III STUDY TOP-LINE RESULTS WITH RHB-104 FOR CROHNâ€™S DISEASE\n* QTRLY LOSS PER ORDINARY SHARE $0.05 * CASH BALANCE AS OF MARCH 31, 2018 WAS $36.4 MILLION, COMPARED TO $46.2 MILLION AS OF DECEMBER 31, 2017 Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-05-08T19:30:00.000+03:00", "crawled": "2018-05-09T12:28:42.009+03:00", "highlightTitle": ""}